Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Xiamen University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07031154CT.gov A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06700421CT.gov Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | — | Active Not Recruiting | — | — | — |
NCT05932264CT.gov Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04878107CT.gov SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy | — | Unknown | — | — | — |
NCT04968002CT.gov Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | — | Unknown | — | — | — |
NCT04950400CT.gov A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC | — | Unknown | — | — | — |
NCT04670913CT.gov Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy | — | Unknown | — | — | — |
NCT04749394CT.gov A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | — | Unknown | — | — | — |
NCT04506242CT.gov Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03801200CT.gov Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC | — | Unknown | — | — | — |
Show 31 more trialsShow fewer
NCT03758677CT.gov Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | — | Unknown | — | — | — |
NCT04203485CT.gov Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT04390984CT.gov Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | — | Unknown | — | — | — |
NCT04133337CT.gov Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | — | Unknown | — | — | — |
NCT03777124CT.gov Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03792503CT.gov Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen | — | Withdrawn | — | — | — |
NCT04239443CT.gov Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | — | Unknown | — | — | — |
NCT03389256CT.gov Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC | — | Unknown | — | — | — |
NCT03811054CT.gov The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT03634059CT.gov A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations | — | Unknown | — | — | — |
NCT03461185CT.gov Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03428022CT.gov Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC | — | Unknown | — | — | — |
NCT03267654CT.gov Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | — | Unknown | — | — | — |
NCT03256721CT.gov Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC | — | Terminated | — | — | — |
NCT03190239CT.gov Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients | — | Withdrawn | — | — | — |
NCT03127319CT.gov A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | — | Unknown | — | — | — |
NCT03201146CT.gov Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | — | Unknown | — | — | — |
NCT03376191CT.gov Apatinib in Advanced Non-squamous，NSCLC | — | Unknown | — | — | — |
NCT03083041CT.gov A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | — | Completed | — | — | — |
NCT03652857CT.gov Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03129256CT.gov An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03416231CT.gov Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | — | Unknown | — | — | — |
NCT02974933CT.gov Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03384511CT.gov The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | — | Completed | — | — | — |
NCT02780778CT.gov Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02733107CT.gov The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02515435CT.gov The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02540824CT.gov Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02332512CT.gov Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) | — | Unknown | — | — | — |
NCT01287962CT.gov Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT01270386CT.gov A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivoceranib (this asset) | The First Affiliated Hospital of Xiamen University | Approved | BB · 64 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Rivoceranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastric Cancer | — | P4 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 72 |
| Cancer | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivoceranib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivoceranib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →